Correction: The HIV-Brazil cohort study: Design methods and participant characteristics, methods and participant characteristics (PLoS ONE (2014) 9, 5 (e95673) DOI: 10.1371/journal.pone.0095673);The HIV-Brazil Cohort study: Design, methods and participant characteristics

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Grangeiro, Alexandre ^a   Escuder, Maria Mercedes ^b   Cassanote, Alex Jones Flores ^a   Souza, Rosa Alencar ^c   Kalichman, Artur O ^c   Veloso, Valdiléa ^d   Ikeda, Maria Letícia Rodrigues ^e   Barcellos, Nêmora Tregnago ^e   Brites, Carlos ^f   Tupinanbás, Unai ^g   Lucena, Noaldo O ^h   Da Silva, Carlos Lima ⁱ   Lacerda, Heloisa Ramos ^j   Grinsztejn, Beatriz ^d   Castilho, Euclides Ayres ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto de Saude de Sao Paulo   (Brazil)

^c STD AIDS Referral and Training Center Department of Health   (Brazil)

^d Funda??o Oswaldo Cruz   (Brazil)

^e Care and Treatment Clinic of the Partenon Sanatorium Rio Grande do Sul State Department of Health   (Brazil)

^f FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^g FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^h Tropical Medicine   (Brazil)

ⁱ State Centre for Diagnosis Treatment and Research Bahia State Department of Health   (Brazil)

^j FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LOPINAVIR; RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BRAZIL; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEALTH CARE FACILITY; HEALTH SERVICE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; VERY ELDERLY; VIRUS REPLICATION; ADOLESCENT; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMORBIDITY; FOLLOW UP; GEOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; TRANSMISSION; TREATMENT OUTCOME; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; GEOGRAPHY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; QUALITY OF LIFE; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84900441193     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104119     Document Type: Erratum

References (24)

1. Teixeira PR, Vitória MA, Barcarolo J (2004) Antiretroviral treatment in resource-poor setting: the Brazilian experience. AIDS (suppl 3): S5-S7. (Pubitemid 39037452)
2. Hacker MA, Kaida A, Hogg RS, Bastos FI (2007) The first tem years: achievements and challenges of the Brazilian program of universal access to HIV/AIDS comprehensive management and care, 1996-2006. Cad Saúde Pública (suppl 3): S345-59.
3. Okie S (2006) Fighting HIV: lessons from Brazil. N Engl J Med 354(19): 1977- 81.
4. Nunn AS, Fonseca EM, Bastos FI, Gruskin S (2009) AIDS Treatment In Brazil: impacts and challenges. Health Affairs 28(4): 1103-13.
5. Greco DB, Simão M (2007) Brazilian policy of universal access to AIDS treatment: sustainability challenge and perspectives. AIDS (suppl 4): S37-S45.
6. Pacheco AG, Tuboi SH, Faulhaber JC, Harrison LH, Schechter M (2008) Increase in non-AIDS related conditions as causes of death among HIV-infected individuals in the HAART era in Brazil. PLoS One 3(1): e1531.
7. Rezende ELLF, Vasconcelos AMN, Pereira MG (2010) Causes of death among people living with HIV/AIDS in Brazil. Braz J Infect Dis 14(6): 558-563.
8. Belloso WH, Orellana LC, Grinsztejn B, Madero JS, La Rosa A, et al. (2010) Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites. HIV Medicine 11(9): 554-64.
9. Veras MASM, Ribeiro MCA, Jamal LF, McFarland W, Bastos FI, et al. (2011) The "AMA-Brazil" cooperative project: a national-wide assessment of the clinical and epidemiological profile of AIDS-related deaths in Brazil in the antiretroviral treatment era. Cad Saude Pública (suppl 1): S104-S113.
10. Guibu IA, Barros MBA, Donalísio MR, Tayara A, Alves MCGP (2011) Survival of AIDS patients in the Southeast and South of Brazil: analysis of the 1998-1999 cohort. Cad Saúde Pública (suppl 1): S79-S92.
11. Silva ACAL, Rodrigues BSC, Micheletti AMR, Tostes S, Meneses ACO, et al. (2012) Neuropathology of AIDS: an autopsy review of 284 cases from Brazil comparing the finding pre- and post-HAART (highly active antiretroviral therapy) and pre- and post-mortem correlation. AIDS Research and Treatment DOI: 10.1155/2012/186850.
12. Grinsztejn B, Luz PM, Pacheco AG, Santos DV, Velasque L, et al. (2013) Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One 8(4): e59768.
13. Torres TS, Cardoso SW, Velasque LS, Marins LM, Oliveira MS, et al. (2013) Aging with HIV: an overview of an urban cohort in Rio de Janeiro (Brazil) across decades of life. Braz J Infect Dis 17(3): 324-31.
14. Grangeiro A, Escuder MM, Menezes PR, Alencar R, Castilho EA (2011) Late entry into HIV care: estimated impact on AIDS mortality rates in Brazil, 2003-2006. PLoS One 6(1): e14585.
15. Malta M, Bastos FI, Silva CMFP, Pereira GF, Lucena FF, et al. (2009) Differential survival benefit of universal HAART access in Brazil: a nationalwide comparison of injection drug users versus men who have sex with men. JAIDS 52(5): 629-35.
16. Portela MC, Lotrowska M (2006) Heath Care to HIV/AIDS patients in Brazil. Rev Saúde Pública 40(suppl): 70-79. (Pubitemid 43797098)
17. Soares MA, Brindeiro RM, Tanuri A (2004) Primary HIV-1 drug resistance in Brazil. AIDS (suppl 3): S9-S13. (Pubitemid 39037453)
18. Inocêncio LA, Pereira AA, Sucupira MCA, Fernandes JCC, Jorge CP, et al. (2009) Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV. J Int AIDS Soc 12: 20. DOI: 10.1186/1758-2652-12-20.
19. Maruza M, Albuquerque MFPM, Braga MC, Barbosa MTS, Byington R, et al. (2012) Survival of HIV-infected patients after starting tuberculosis treatment: a prospective cohort study. Int J Tuberc Lung Dis 16(5): 618-24.
20. Ribeiro FA, Tupinambás U, Fonseca MO, Greco DB (2012) Durability of the combined antiretroviral regimen in patients with AIDS at a reference center in Belo Horizonte, Brazil, from 1996 to 2005. Braz J Infect Dis 16(1): 27-33.
21. Alencastro PR, Fuchs SC, Wolf FH, Ikeda LM, Brandão ABM, et al. (2011) Independent predictors of metabolic syndrome in HIV-infected patients. AIDS Patient Care STDs 25(11): 627-634.
22. Miranda A, Morgan M, Jamal L, Laserson K, Barreira D, et al. (2005) Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS ONE 2(9): e826. DOI: 10.1371/journal.pone.0000826.
23. Hofer CB, Schechter M, Harrison LH (2004) Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 36(4): 967-71. (Pubitemid 38944093)
24. Medeiros R, Diaz RS, Filho AC (2002) Estimating the length of the first antiretroviral therapy regiment durability in São Paulo Brazil. BJID 6(6): 298-304.